Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines development, has announced its participation in the BofA Securities Healthcare Conference 2025 in Las Vegas from May 13-15, 2025. The company's management team will conduct one-on-one meetings and participate in a fireside chat on May 14, 2025, from 11:40 am to 12:10 pm EDT. A live audio webcast of the chat will be available to the public through Alvotech's investor relations website, with a replay accessible for 90 days post-event.
Alvotech (NASDAQ: ALVO), un'azienda biotecnologica globale specializzata nello sviluppo di farmaci biosimilari, ha annunciato la sua partecipazione alla BofA Securities Healthcare Conference 2025 a Las Vegas, dal 13 al 15 maggio 2025. Il team dirigenziale dell'azienda terrà incontri individuali e parteciperà a una tavola rotonda informale il 14 maggio 2025, dalle 11:40 alle 12:10 EDT. Una trasmissione audio in diretta sarà disponibile al pubblico tramite il sito web delle relazioni con gli investitori di Alvotech, con la possibilità di rivederla per 90 giorni dopo l'evento.
Alvotech (NASDAQ: ALVO), una compañía biotecnológica global enfocada en el desarrollo de medicamentos biosimilares, ha anunciado su participación en la BofA Securities Healthcare Conference 2025 en Las Vegas, del 13 al 15 de mayo de 2025. El equipo directivo de la empresa realizará reuniones individuales y participará en una charla informal el 14 de mayo de 2025, de 11:40 a 12:10 EDT. Una transmisión de audio en vivo estará disponible para el público a través del sitio web de relaciones con inversores de Alvotech, con una repetición accesible durante 90 días después del evento.
Alvotech (NASDAQ: ALVO)는 바이오시밀러 의약품 개발에 중점을 둔 글로벌 바이오텍 기업으로, 2025년 5월 13일부터 15일까지 라스베이거스에서 열리는 BofA Securities Healthcare Conference 2025에 참여한다고 발표했습니다. 회사 경영진은 2025년 5월 14일 오전 11시 40분부터 12시 10분(동부 표준시)까지 일대일 미팅과 파이어사이드 채팅에 참여할 예정입니다. 이 채팅은 Alvotech 투자자 관계 웹사이트를 통해 라이브 오디오 웹캐스트로 공개되며, 행사 종료 후 90일 동안 다시보기 서비스가 제공됩니다.
Alvotech (NASDAQ : ALVO), une entreprise biotechnologique mondiale spécialisée dans le développement de médicaments biosimilaires, a annoncé sa participation à la BofA Securities Healthcare Conference 2025 à Las Vegas, du 13 au 15 mai 2025. L'équipe de direction de la société tiendra des réunions individuelles et participera à une discussion informelle le 14 mai 2025, de 11h40 à 12h10 EDT. Une diffusion audio en direct de cette discussion sera accessible au public via le site web des relations investisseurs d'Alvotech, avec une rediffusion disponible pendant 90 jours après l'événement.
Alvotech (NASDAQ: ALVO), ein globales Biotechnologieunternehmen, das sich auf die Entwicklung von Biosimilars spezialisiert hat, hat seine Teilnahme an der BofA Securities Healthcare Conference 2025 in Las Vegas vom 13. bis 15. Mai 2025 angekündigt. Das Management-Team des Unternehmens wird Einzelgespräche führen und am 14. Mai 2025 von 11:40 bis 12:10 Uhr EDT an einem Fireside-Chat teilnehmen. Ein Live-Audio-Webcast des Gesprächs wird der Öffentlichkeit über die Investor-Relations-Website von Alvotech zugänglich sein, mit einer Wiedergabe, die bis zu 90 Tage nach der Veranstaltung verfügbar ist.
- None.
- None.
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the BofA Securities Healthcare Conference 2025, which will be held in Las Vegas, Nevada, May 13-15, 2025. Members of the management team will host one-on-one meetings at the conference. Alvotech will also be participating in a fireside chat on Wednesday, May 14, 2025, at 11:40 am -12:10 pm EDT (15:40-16:10 GMT / 17:40-18:10 CET).
A live audio webcast of the fireside chat will also be available to the general public and can be accessed at https://investors.alvotech.com/events/event-details/bofa-securities-healthcare-conference-2025. After the event, a recording will be available for replay for 90 days.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Biogaran (FR), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com.
Please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, and YouTube.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
alvotech.ir@alvotech.com
FAQ
When is Alvotech (ALVO) presenting at the BofA Securities Healthcare Conference 2025?
How can investors watch Alvotech's presentation at the BofA Healthcare Conference 2025?
What type of meetings will Alvotech's management team conduct at the BofA Conference 2025?
Where is the BofA Securities Healthcare Conference 2025 with Alvotech being held?
